Patents Assigned to Merck
  • IL4I1 INHIBITORS AND METHODS OF USE
    Publication number: 20240246937
    Abstract: The invention discloses a synthesizing method of benzimidazole derivant and intermediate, which is characterized by the following: proceeding arylation among aryl halide and primary amine; adopting L-pro as additive, cuprous iodide as catalyst; proceeding molecular arylation coupling reaction for aryl iodide or aryl bromide and primary amine; adopting iodo phenylamine compound and bromophenylamine compound as starting material; synthesizing the material through several-step transformation.
    Type: Application
    Filed: April 28, 2022
    Publication date: July 25, 2024
    Applicants: MERCK SHARP & DOHME LLC, MSD R&D (CHINA) CO., LTD.
    Inventors: George Madalin GIAMBASU, Andrew M. HAIDLE, Brett A. HOPKINS, James P. JEWELL, Matthew A. LARSEN, Charles A. LESBURG, Ping LIU, Qinglin PU, Sulagna SANYAL, Phieng SILIPHAIVANH, Matthew TUDOR, Catherine M. WHITE, Xin YAN, Lianyun ZHAO, Xiao Mei ZHENG, William P. KAPLAN, Michaelyn Claire LUX, Derun LI, Rebecca JOHNSON
  • METHODS OF TREATMENT OF CANCER PATIENTS HAVING ALTERED SETD2 BIOMARKER WITH A PD-1 ANTAGONIST
    Publication number: 20240247065
    Abstract: The present disclosure describes methods of treatment of cancer in patients with altered activity or amount of a SETD2 biomarker with a treatment regimen comprising an antagonist of Programmed Death 1 receptor (PD-1).
    Type: Application
    Filed: May 16, 2022
    Publication date: July 25, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Razvan CRISTESCU, Elisha DETTMAN, Yongjin LI, Karla Gabriela RODRIGUEZ-LOPEZ, Michael NEBOZHYN, Rodolfo Fleury PERINI, Raluca Andreia PREDOIU, Yiwei ZHANG
  • Liquid-crystalline medium
    Patent number: 12043781
    Abstract: Liquid-crystalline (LC) media having positive dielectric anisotropy and liquid-crystal displays (LCDs) containing these media, especially displays addressed by an active matrix and in particular to LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: July 23, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Sven Christian Laut, Sabrina Pfeiffer, Philipp Hans Fackler
  • Liquid crystalline medium
    Patent number: 12043782
    Abstract: The present invention relates to a liquid crystalline medium comprising dichroitic dyes made of benzothiadiazoles and related extended heterocyclic derivatives, the use of said medium for optical, electro-optical and electronic purposes, in particular in devices for regulating the passage of radiation energy from an outside space into an inside space, for example in windows. The invention further relates to devices containing the liquid crystalline medium according to the invention. Some new dichroitic dyes are disclosed.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: July 23, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph Wetzel, Peer Kirsch, Susann Gunst, Andreas Ruhl, Andrea Ritter, Rene Lutz, Michael Junge
  • Two bit memory device and method for operating the two-bit memory device and electronic component
    Patent number: 12046269
    Abstract: A two-bit memory device having a layer structure containing in order a bottom layer, a molecular layer containing a chiral compound having at least one polar functional group, and a top layer, which is electrically conductive and ferromagnetic. The chiral compound acts as a spin filter for electrons passing through the molecular layer. The chiral compound is of flexible conformation and has a conformation-flexible molecular dipole moment. An electrical resistance of the layer structure for an electrical current running from the bottom layer to the top layer has at least four distinct states which depend on the magnetization of the top layer and on the orientation of the conformation-flexible dipole moment of the chiral compound. Furthermore, a method for operating the two-bit memory device and an electronic component containing at least one two-bit memory device.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: July 23, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Peer Kirsch, Sebastian Resch, Henning Seim, Itai Lieberman, Marc Tornow, Julian Dlugosch, Takuya Kamiyama
  • Composition comprising semiconducting light emitting nanoparticles
    Patent number: 12043761
    Abstract: A method of manufacturing a composition with improved quantum yield, containing at least these steps: a/ manufacturing a mixture by at least these steps: 1/ providing a semiconducting light emitting nanoparticle, 2/ adding a macromolecular compound comprising at least an anchoring group; 3/ adding an organic additive, and b/ subjecting the mixture from step a/ to irradiation with light of a wavelength in the range of 300 to 600 nm having an intensity in the range of 0.025 to 1 W/cm2 to obtain the composition; wherein the organic additive is defined by formula (Ia): M-(X—Y)2, wherein M is a divalent metal ion, X is a hydrocarbon chain, and Y is a functional group.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: July 23, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Denis Glozman, Ehud Shaviv, Yuki Hirayama, Teruaki Suzuki, Christian-Hubertus Kuechenthal
  • Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors
    Patent number: 12036203
    Abstract: The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: July 16, 2024
    Assignees: Merck Sharp & Dohme LLC, Pfizer Inc.
    Inventors: Brett Lauring, Samuel S. Engel, Steven G. Terra, James M. Rusnak
  • P116 antibodies
    Patent number: 12037393
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind PI16 and block binding of ILT3 to PI16.
    Type: Grant
    Filed: May 16, 2022
    Date of Patent: July 16, 2024
    Assignee: Merck Sharpe & Dohme LLC
    Inventors: Daniel Cua, Holly Cherwinski, Adele Wang, Yi Chen, Barbara Joyce-Shaikh
  • Enzymatic synthesis of 4?-ethynyl nucleoside analogs
    Patent number: 12037623
    Abstract: The present invention relates to an enzymatic synthesis of 4?-ethynyl-2?-deoxy nucleosides and analogs thereof, for example EFdA, that eliminates the use of protecting groups on the intermediates, improves the stereoselectivity of glycosylation and reduces the number of process steps needed to make said compounds. It also relates to the novel intermediates employed in the process.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: July 16, 2024
    Assignee: Merck, Sharp & Dohme LLC
    Inventors: Mark A. Huffman, Anna Fryszkowska, Joshua N. Kolev, Paul N. Devine, Kevin R. Campos, Matthew Truppo, Christopher C. Nawrat
  • Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
    Patent number: 12037333
    Abstract: Provided herein are compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: July 16, 2024
    Assignees: COCRYSTAL PHARMA, INC., MERCK SHARP & DOHME LLC
    Inventors: Irina C. Jacobson, Biing Yuan Lin, Emiliano J. Sanchez, Sam S K Lee, Hong Xiao
  • RIPK1 INHIBITORS AND METHODS OF USE
    Publication number: 20240228506
    Abstract: Described herein are compounds of Formula II, or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: April 21, 2022
    Publication date: July 11, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Erin F. DiMauro, Xavier Fradera, Peter H. Fuller, Min Lu, Joey L. Methot, Matthew J. Mitcheltree, Andrew J. Musacchio, Phieng Siliphaivanh, Jing Su
  • PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION
    Publication number: 20240228535
    Abstract: The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: November 20, 2023
    Publication date: July 11, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: John J. Acton, III, Mayuri Gupta, Michael J. Kelly, III, Franca-Maria Klingler, Mark Eric Layton, John A. McCauley, Gregori J. Morriello, Christopher Charles Nawrat, Craig A. Parish, Anthony J. Roecker, Manuel de Lera Ruiz, Jing Su, Valerie W. Shurtleff, Quang T. Truong
  • LIQUID-CRYSTALLINE MEDIUM
    Publication number: 20240228877
    Abstract: Liquid-crystalline (LC) media having positive dielectric anisotropy and liquid-crystal displays (LCDs) containing these media, especially displays addressed by an active matrix and in particular energy saving LC displays of the TN, PS-TN, STN, TN-TFT, OCB, IPS, PS-IPS, FFS, HB-FFS, XB-FFS, PS-FFS, SA-HB-FFS, SA-XB-FFS, polymer stabilised SA-HB-FFS, polymer stabilised SA-XB-FFS, positive VA or positive PS-VA type. The media have an improved long-term stability against UV radiation and elevated temperatures.
    Type: Application
    Filed: December 6, 2023
    Publication date: July 11, 2024
    Applicant: Merck Patent GmbH
    Inventors: Yeon-Jeong Han, Dong-Hyun Kim, Sang-Hyun Park, Sun-Mi Park, Heui-Seok Jin
  • BLOW-FILL SEALING METHOD FOR FILLING AND PACKAGING
    Publication number: 20240226439
    Abstract: A method of controlling a temperature of a biopharmaceutical product during blow-fill sealing, includes developing a model based on heat transfer mechanisms that incorporates the effects of the blow-fill sealing on the biopharmaceutical product, providing a parison to a blow-fill sealing machine for accepting the biopharmaceutical product during the blow-fill sealing, predicting a temperature of at least one the biopharmaceutical product, the parison, and a component of the blow-fill sealing machine at a stage in the blow-fill sealing, and adjusting a parameter of the blow-fill sealing machine to reduce damage to the biopharmaceutical product.
    Type: Application
    Filed: October 11, 2023
    Publication date: July 11, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Carl Chew, Matthew H. Flamm, Jeremy A. Haddock, Rikhabh Jain, Atul Karande, Brit L. Rudeen
  • ANTI-ILT4 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
    Publication number: 20240228614
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.
    Type: Application
    Filed: December 20, 2023
    Publication date: July 11, 2024
    Applicants: Merck Sharp & Dohme LLC, Agenus Inc.
    Inventors: Milan Blanusa, Barbara Joyce-Shaikh, Andrea Claudia Schuster, Kornelia Schultze, Luis A. Zuniga
  • EGFR TARGETING FC ANTIGEN BINDING FRAGMENT-DRUG CONJUGATES
    Publication number: 20240226319
    Abstract: The invention relates to EGFR targeting Fc antigen binding fragment-drug conjugates (EGFR Fcab-drug conjugates) and the use of the EGFR Fcab-drug conjugates of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such EGFR Fcab-drug conjugates. Further, the invention relates to EGFR Fcab-label conjugates and diagnostic compositions containing such EGFR Fcab-label conjugates.
    Type: Application
    Filed: May 23, 2022
    Publication date: July 11, 2024
    Applicant: MERCK PATENT GMBH
    Inventors: Sebastian JAEGER, Christian SCHROETER
  • COMBINATION THERAPIES FOR TREATING CANCER
    Publication number: 20240226082
    Abstract: The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 11, 2024
    Applicants: TESARO, Inc., MERCK SHARP & DOHME B.V.
    Inventors: Dmitri Bobilev, Bruce Dezube, Peng Sun, Andrew R. Ferguson
  • NOVEL TREATMENT REGIMEN FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
    Publication number: 20240226284
    Abstract: A novel treatment regimen is provided for the treatment of autoimmune disorders. Said novel treatment regimen provides for an efficacious treatment of autoimmune disorders with an advantageous safety profile and/or a high quality of life for the patient. Said novel treatment regimen provides for an advantageous benefit-risk ratio for patients endangered by the risk of infections.
    Type: Application
    Filed: September 10, 2021
    Publication date: July 11, 2024
    Applicant: Merck Patent GmbH
    Inventors: Ursula Boschert, Urs Wiedermann
  • Materials for organic electroluminescent devices
    Patent number: 12035625
    Abstract: The invention relates to compounds of formula (1) which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds. X is, identically or differently in each occurrence, CR or N, or two adjacent X stand for a group of the following formula (2), wherein the dashed bonds mark the bonding of said group in formula (1), with the stipulation that the compound of formula (1) contains one or two groups of formula (2); X1 is, identically or differently in each occurrence, CR or N; Y is, identically or differently in each occurrence, CR or N; Z1, Z2, Z3 are, identically or differently in each occurrence, O, S, N—Ar or CR2.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: July 9, 2024
    Assignee: Merck Patent GmbH
    Inventors: Amir Parham, Christian Eickhoff, Rouven Linge, Jens Kaiser, Amel Mekic
  • Switching layer for use in an optical switching element
    Patent number: 12031078
    Abstract: The present invention relates to a switching layer based on a liquid-crystalline mixture for use in an optical switching element. The invention also encompasses a switching element comprising the switching layer and a window element containing the switching element. The liquid crystalline mixture comprises a low-molecular liquid crystal component, a polymer component and a self-alignment additive for vertical alignment.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: July 9, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Dong-Mee Song, Jung-Min Lee, Yong-Hyun Choi, Yong-Kuk Yun